Video
Author(s):
Claire Harrison, MD, reviews the use of ruxolitinib in patients who are ineligible for hydroxycarbamide for the management of polycythemia vera (PV).
FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation
Revisit the OncLive On Air Episodes From February 2024
FDA Approves Nilotinib Tablets Without Mealtime Restrictions for CML
Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma
Real-World Experience With CAR T Varies From Trials in DLBCL
Revumenib Meets CR/CRh End Point in NPM1+ R/R AML
Dr Caimi on Early Data for LMY-920 in R/R B-Cell NHL
Navigating a “Sea Change” in Frontline Urothelial Carcinoma Treatment
Dr Scalici on Data for IMNN-001 Plus SOC Chemotherapy in Advanced Ovarian Cancer
Dr Lin on the Safety of NKTR-255 in Enhancing Immune Recovery Post-Chemoradiation in Locally Advanced NSCLC